U.S. biosimilars intelligence — delivered in a format teams actually use.
ATB helps teams track what matters in the U.S. biosimilars market with consistent reporting, clear framing, and referenceable insight that supports real decisions.
A weekly signal, not noise.
The U.S. biosimilars market moves fast — pricing shifts, payer behavior, launches, policy updates, and competitive dynamics. ATB turns that complexity into a consistent weekly read so teams can stay aligned without rebuilding the story from scratch each week.
What you get
Explore the 351(k) Report →Timely insights
Week-to-week market changes captured on a consistent cadence.
Unparalleled experience
Underpinned by 15+ years focused exclusively on U.S. biosimilars.
Robust analysis
Synthesis across news, primary sources, datasets, and intelligent tools.
Built for teams that need clarity fast.
Brand & strategy
Stay current on launches, competitive moves, and market signals without chasing fragments.
Market access
Track pricing and reimbursement dynamics in a repeatable format built for real decisions.
CI & analytics
Use consistent weekly framing to prioritize what’s worth deeper follow-up and analysis.
Access for subscribers.
ATB is designed for ongoing use — a consistent cadence, a growing archive, and a single place to revisit prior issues once logged in.
Designed to move from idea to execution.
All Things Biosimilar is designed and built by Bourgoin Insights Group (BIG). BIG partners with organizations to define strategy and build the systems that support it — with a focus on efficiency, clarity, and real execution. ATB is one example of that approach in practice.
Ready to get oriented?
Start with the latest reports, or log in to access subscriber content.